Kenneth Simmen

2.3k citations

39 papers · 1.6k indexed · h-index 20

Hepatology top 1%
- Hepatitis C virus research 23
Epidemiology top 5%
- Hepatitis B Virus Studies 11
- Liver Disease Diagnosis and Treatment 5
- Herpesvirus Infections and Treatments 4
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment 9
Virology top 10%
- HIV Research and Treatment 6
Immunology
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 7
Molecular Biology
- RNA Research and Splicing 5

Co-authors: Oliver Lenz Iain W. Mattaj Jordi Bernués Gregory Fanning Pierre Raboisson Herman de Kock Tse‐I Lin Thierry Verbinnen
Cited by: Hepatology Epidemiology Infectious Diseases
Journals: Journal of Hepatology (6 papers)Journal of Virology (5 papers)Antimicrobial Agents and Chemotherapy (4 papers)
Partner nations: Belgium United States Germany

In The Last Decade

Kenneth Simmen

39 papers receiving 1.6k citations

Peers

Countries citing papers authored by Kenneth Simmen

Since Specialization

Citations

This map shows the geographic impact of Kenneth Simmen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Simmen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Simmen more than expected).

Fields of papers citing papers by Kenneth Simmen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Simmen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Simmen. The network helps show where Kenneth Simmen may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kenneth Simmen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kenneth Simmen Line = papers co-authored together Kenneth Simmen links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Characterization of a dengue NS4B inhibitor originating from an HCV small molecule library Antiviral Research ·滋成長谷川,Peggy Geluykens,خـاسف جمال الدين,清策森田,Olivia Goethals,Bilinç Doğruöz Karatekin,T. Prazuck,Stefaan Last,David C. McGowan,Thomas Koellner,Benoît De Boeck,Bart Stoops,Benoit Devogelaere,Frederik Pauwels,Koen Vandyck,Jan Martin Berke,Pierre Raboisson,Kenneth Simmen,Péter Hajnal,Marnix Van Loock	2017	15
2	Synthesis and evaluation of novel HCV replication inhibitors Molecular Diversity ·David C. McGowan,宏臣廣野,Alex De Groot,Frederik Pauwels,Frédéric Delouvroy,Kristof Van Emelen,Kenneth Simmen,Pierre Raboisson	2017	2
3	Antiviral Activity of TMC353121, a Respiratory Syncytial Virus (RSV) Fusion Inhibitor, in a Non-Human Primate Model PLoS ONE ·Gabriela Ispas,Anil Koul,Johan Verbeeck,Hiroyuki Yasukochi,Brigitte E. Sanders-Beer,Dirk Roymans,Koen Andries,M.C. Rouan,Sandra De Jonghe,Jean‐François Bonfanti,李向英,Kenneth Simmen,René Verloes	2015	35
4	Safety and Pharmacokinetics of the HIV-1 Protease Inhibitor TMC310911 Coadministered With Ritonavir in Healthy Participants JAIDS Journal of Acquired Immune Deficiency Syndromes ·Richard M. W. Hoetelmans,Inge Dierynck,Romain Lauzeral,Paul Meyvisch,Qiuju,Martine Bubb,Kenneth Simmen,René Verloes	2013	3
5	Innentitelbild: Induced‐Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target (Angew. Chem. 9/2010) Angewandte Chemie ·Maxwell D. Cummings,Jimmy Lindberg,Tse‐I Lin,Herman de Kock,Oliver Lenz,Dirk Zerwas,Gelan Negash,Vera Baraznenok,Susanne Nyström,Magnus Nilsson,Lotta Vrang,Michael Edlund,Åsa Rosenquist,Bertil Samuelsson,Pierre Raboisson,Kenneth Simmen	2010	1
6	Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients Gastroenterology ·H. W. Reesink,Gregory Fanning,Sabina Grincevičiūtė,Christine J. Weegink,André van Vliet,Gerben van ‘t Klooster,Oliver Lenz,Yuan-tsung Chen,Martine Bubb,P. Van Remoortere,Herman de Kock,F. Broeckaert,Paul Meyvisch,Grace D. Surantos,Kenneth Simmen,René Verloes	2009	123
7	In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor Antimicrobial Agents and Chemotherapy ·Tse‐I Lin,Oliver Lenz,Gregory Fanning,Thierry Verbinnen,Frédéric Delouvroy,Annick Scholliers,Katrien Vermeiren,Åsa Rosenquist,Michael Edlund,Bertil Samuelsson,Lotta Vrang,Herman de Kock,Piet Wigerinck,Pierre Raboisson,Kenneth Simmen	2009	142
8	855 ONCE-DAILY REGIMENS OF THE HCV NS3/4A-PROTEASE INHIBITOR TMC435350 ARE PREDICTED TO PROVIDE THERAPEUTIC EXPOSURE IN PLASMA AND LIVER Journal of Hepatology ·Shapoor Hamid,Per Ljungberg,Christopher Leon Guerrero,P.K.G. de Bruyne,Marieke Voets,Jos Van Houdt,René Verloes,Yuan-tsung Chen,Martine Bubb,P. Van Remoortere,F. Broeckaert,Herman de Kock,Kenneth Simmen	2008	3
9	Safety and Antiviral Activity of Tmc435350 in Treatment-name Genotype 1 Hcv-infected Patients Hepatology ·Michael P. Manns,Yves Horsmans,Hendrik W. Reesink,Christophe Moreno,Thomas Berg,Yves Benhamou,Geoffrey Dusheiko,Robert Flisiak,Paul Meyvisch,Oliver Lenz,Kenneth Simmen,René Verloes	2008	3
10	Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors Bioorganic & Medicinal Chemistry Letters ·Pierre Raboisson,Tse‐I Lin,Herman de Kock,Sandrine Vendeville,Caitlyn Tabor,David C. McGowan,Abdellah Tahri,Lili Hu,Oliver Lenz,Frédéric Delouvroy,Dominique Surleraux,Piet Wigerinck,Magnus Nilsson,Åsa Rosenquist,Bertil Samuelsson,Kenneth Simmen	2008	18
11	64 SAFETY OF THE HCV PROTEASE INHIBITOR TMC435350 IN HEALTHY VOLUNTEERS AND SAFETY AND ACTIVITY IN CHRONIC HEPATITIS C INFECTED INDIVIDUALS: A PHASE I STUDY Journal of Hepatology ·Hendrik W. Reesink,René Verloes,Sabina Grincevičiūtė,MSc. Lukman Hanafi,Christine J. Weegink,Gerben van ‘t Klooster,Yuan-tsung Chen,Martine Bubb,P. Van Remoortere,Herman de Kock,F. Broeckaert,Gregory Fanning,Paul Meyvisch,Grace D. Surantos,Kenneth Simmen	2008	16
12	Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Pierre Raboisson,Oliver Lenz,Tse‐I Lin,Dominique Surleraux,Sarvajit Chakravarty,Annick Scholliers,Katrien Vermeiren,Frédéric Delouvroy,Thierry Verbinnen,Kenneth Simmen	2007	11
13	Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase Inhibitors Journal of Virology ·Frederik Pauwels,Wendy Mostmans,Minxian Bao,Liesbet van der Helm,Carlo Boutton,SeyedBehzad Jazayeri,Erna Cleiren,Pierre Raboisson,Dominique Surleraux,Origène Nyanguile,Kenneth Simmen	2007	55
14	Application of the trak-C™ HCV core assay for monitoring antiviral activity in HCV replication systems Journal of Virological Methods ·Laurence Cagnon,Pamela C. Wagaman,Ralf Bartenschlager,Thomas Pietschmann,Tiejun Gao,Norman M. Kneteman,David Tyrrell,Chander P. Bahl,JongWon Hwang,Stephen Lee,Kenneth Simmen	2004	15
15	Development of a novel influenza A antiviral assay Journal of Virological Methods ·Pamela C. Wagaman,César A. Gallo Gómez,Kenneth Simmen	2002	14
16	Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B Proceedings of the National Academy of Sciences ·Kenneth Simmen,Jasbir Singh,B. G. Mattias Luukkonen,Diana Carolina Santos Durán,Anton Bittner,Nancy E. Miller,Michael R. Jackson,Teresa Compton,Klaus Früh	2001	176
17	Virogenomics: a novel approach to antiviral drug discovery Drug Discovery Today ·Klaus Früh,Kenneth Simmen,B. G. Mattias Luukkonen,Karine Fausto Gonzalez,Peter Ghazal	2001	20
18	Proximal sequence element factor binding and species specificity in vertebrate U6 snRNA promoters Journal of Molecular Biology ·Kenneth Simmen,Rainer Waldschmidt,Jordi Bernués,Huw D. Parry,Klaus H. Seifart,Iain W. Mattaj	1992	35
19	Cofractionation of the TATA-binding protein with the RNA polymerase III transcription factor TFIIIB Nucleic Acids Research ·Kenneth Simmen,Jordi Bernués,Joe Lewis,Iain W. Mattaj	1992	48
20	TFIID is required for in vitro transcription of the human U6 gene by RNA polymerase III. The EMBO Journal ·Kenneth Simmen,Jordi Bernués,Huw D. Parry,Hendrik G. Stunnenberg,Anders Berkenstam,Bruno Cavallini,Jean‐Marc Egly,Iain W. Mattaj	1991	119

About Kenneth Simmen

Kenneth Simmen is a scholar working on Hepatology, Virology, Infectious Diseases, Epidemiology and Radiology, Nuclear Medicine and Imaging, having authored 39 papers that have together received 1.6k indexed citations. Recurring topics across this work include Hepatitis C virus research (23 papers), Hepatitis B Virus Studies (11 papers), HIV/AIDS drug development and treatment (9 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), HIV Research and Treatment (6 papers), Liver Disease Diagnosis and Treatment (5 papers), RNA Research and Splicing (5 papers) and Herpesvirus Infections and Treatments (4 papers). The work is most often cited by research in Hepatology (753 citations), Epidemiology (892 citations), Infectious Diseases (459 citations), Virology (56 citations) and Immunology (192 citations). Kenneth Simmen has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Oliver Lenz, Iain W. Mattaj, Jordi Bernués, Gregory Fanning, Pierre Raboisson, Herman de Kock, Tse‐I Lin, Thierry Verbinnen, Lotta Vrang and B. G. Mattias Luukkonen. Their work appears in journals such as Journal of Hepatology, Journal of Virology, Antimicrobial Agents and Chemotherapy, JAIDS Journal of Acquired Immune Deficiency Syndromes and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact